TrialInternational journal of hematology2019

Combined rituximab, bendamustine, and dexamethasone chemotherapy for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma: a multicenter phase II study.

Yosuke Matsumoto et al.PubMed ↗Publisher ↗

No numbers read from the abstract.